The DOI matches its Crossref record; 413 of the 413 references it cites were found in a registry or an index.
Understanding and targeting resistance mechanisms in cancer
Open accessAbstract
Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can arise from genetic, epigenetic, and microenvironmental factors. Various mechanisms have been discovered and extensively studied, including drug inactivation, reduced intracellular drug accumulation by reduced uptake or increased efflux, drug target alteration, activation of compensatory pathways for cell survival, regulation of DNA repair and cell death, tumor plasticity, and the regulation from tumor microenvironments (TMEs). To overcome cancer resistance, a variety of strategies have been proposed, which are designed to enhance the effectiveness of cancer treatment or reduce drug resistance. These include identifying biomarkers that can predict drug response and resistance, identifying new targets, developing new targeted drugs, combination therapies targeting multiple signaling pathways, and modulating the TME. The present article focuses on the different mechanisms of drug resistance in cancer and the corresponding tackling approaches with recent updates. Perspectives on polytherapy targeting multiple resistance mechanisms, novel nanoparticle delivery systems, and advanced drug design tools for overcoming resistance are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Fu, X., Liu, M., Qu, S., Ma, J., Zhang, Y., Shi, T., Wen, H., Yang, Y., Wang, S., Wang, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0677-7 · Cited by 217
RetractedExosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer
Dong, H., Wang, W., Chen, R., Zhang, Y., Zou, K., Ye, M., He, X., Zhang, F., & Han, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4467 · Cited by 191
RetractedHan, M., Hu, J., Lu, P., Cao, H., Yu, C., Li, X., Qian, X., Yang, X. F., Yang, Y., Han, N., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2250-5 · Cited by 139
RetractedWu, P., Yin, D., Liu, J., Zhou, H., Guo, M., Liu, J., Liu, Y., Wang, X., Liu, Y., & Chen, C. (2019) · Nanoscale · doi:10.1039/c9nr05791a · Cited by 38
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Copper induces cell death by targeting lipoylated TCA cycle proteins
Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., et al. (2022) · Science · doi:10.1126/science.abf0529 · Cited by 4,932
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
The ever‐increasing importance of cancer as a leading cause of premature death worldwide
Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2021) · Cancer · doi:10.1002/cncr.33587 · Cited by 2,591
Exosomes: Extracellular organelles important in intercellular communication
Mathivanan, S., Ji, H., & Simpson, R. J. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.06.006 · Cited by 2,537
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Gaggelli, E., Kozlowski, H., Valensin, D., & Valensin, G. (2006) · Chemical Reviews · doi:10.1021/cr040410w · Cited by 1,729
Phenotype molding of stromal cells in the lung tumor microenvironment
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
The role of pericytes in blood-vessel formation and maintenance
Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Fang, R. H., Hu, C.-M. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O’Connor, D. E., & Zhang, L. (2014) · Nano Letters · doi:10.1021/nl500618u · Cited by 1,501
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Death by design: apoptosis, necrosis and autophagy
Edinger, A. L., & Thompson, C. B. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.09.011 · Cited by 1,364
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance
Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01530-y · Cited by 1,332
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
The Role of Autophagy in Cancer: Therapeutic Implications
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0047 · Cited by 1,215
DNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,167
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28833 · Cited by 1,137
Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria
Dejea, C. M., Fathi, P., Craig, J. M., Boleij, A., Taddese, R., Geis, A. L., Wu, X., DeStefano Shields, C. E., Hechenbleikner, E. M., Huso, D. L., et al. (2018) · Science · doi:10.1126/science.aah3648 · Cited by 1,105
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Wilson's disease and other neurological copper disorders
Bandmann, O., Weiss, K. H., & Kaler, S. G. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70190-5 · Cited by 1,036
GPX4 at the crossroads of lipid homeostasis and ferroptosis
Forcina, G. C., & Dixon, S. J. (2019) · PROTEOMICS · doi:10.1002/pmic.201800311 · Cited by 1,025
Cuproptosis: a copper-triggered modality of mitochondrial cell death
Tang, D., Chen, X., & Kroemer, G. (2022) · Cell Research · doi:10.1038/s41422-022-00653-7 · Cited by 960
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
EMT, cell plasticity and metastasis
Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 861
Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation
Webber, J., Steadman, R., Mason, M. D., Tabi, Z., & Clayton, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1722 · Cited by 852
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., Michellys, P.-Y., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 840
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells
Richards, K. E., Zeleniak, A. E., Fishel, M. L., Wu, J., Littlepage, L. E., & Hill, R. (2017) · Oncogene · doi:10.1038/onc.2016.353 · Cited by 735
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
Visualization and targeting of LGR5+ human colon cancer stem cells
Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017) · Nature · doi:10.1038/nature22081 · Cited by 728
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Non-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 606
Gainor, J. F., Varghese, A. M., Ou, S.-H. I., Kabraji, S., Awad, M. M., Katayama, R., Pawlak, A., Mino-Kenudson, M., Yeap, B. Y., Riely, G. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0318 · Cited by 604
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 563
Advances in cancer immunotherapy 2019 – latest trends
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 563
Structural and Mechanistic Principles of ABC Transporters
Thomas, C., & Tampé, R. (2020) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-011520-105201 · Cited by 563
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Katayama, R., Khan, T. M., Benes, C., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 542
Sethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539
pH-responsive polymer nanoparticles for drug delivery
Deirram, N., Zhang, C., Kermaniyan, S. S., Johnston, A. P. R., & Such, G. K. (2019) · Macromolecular Rapid Communications · doi:10.1002/marc.201800917 · Cited by 531
Optimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Esteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Zheng, D.-W., Dong, X., Pan, P., Chen, K.-W., Fan, J.-X., Cheng, S.-X., & Zhang, X.-Z. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0423-2 · Cited by 495
Lipoic acid metabolism and mitochondrial redox regulation
Solmonson, A., & DeBerardinis, R. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm117.000259 · Cited by 489
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 458
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
Self-citationThe functional activity of E-cadherin controls tumor cell metastasis at multiple steps
Na, T.-Y., Schecterson, L., Mendonsa, A. M., & Gumbiner, B. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918167117 · Cited by 441
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Cheng, F., Shen, Y., Mohanasundaram, P., Lindström, M., Ivaska, J., Ny, T., & Eriksson, J. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519197113 · Cited by 428
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 418
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
Corrado, C., Raimondo, S., Chiesi, A., Ciccia, F., De Leo, G., & Alessandro, R. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035338 · Cited by 396
Shedden, K., Xie, X. T., Chandaroy, P., Chang, Y., & Rosania, G. R. (2003) · PubMed · Cited by 385
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes
Rubino, F., Mutter, D., Marescaux, J., Leroy, J., Jamali, F., Forbes, L., & Smith, M. (2004) · Surgical Endoscopy · doi:10.1007/s00464-002-8877-8 · Cited by 379
O'Day, S. J., Eggermont, A. M. M., Chiarion-Sileni, V., Kefford, R., Grob, J. J., Mortier, L., Robert, C., Schachter, J., Testori, A., Mackiewicz, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5585 · Cited by 373
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma
Tsang, T., Posimo, J. M., Gudiel, A. A., Cicchini, M., Feldser, D. M., & Brady, D. C. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0481-4 · Cited by 371
Transport of glutathione and glutathione conjugates by MRP1
Cole, S. P. C., & Deeley, R. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.06.008 · Cited by 369
Cell membrane modulation as adjuvant in cancer therapy
Zalba, S., & ten Hagen, T. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.008 · Cited by 365
Zhang, H.-G., & Grizzle, W. E. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.09.027 · Cited by 352
Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice
Cui, L., Gouw, A. M., LaGory, E. L., Guo, S., Attarwala, N., Tang, Y., Qi, J., Chen, Y.-S., Gao, Z., Casey, K. M., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0707-9 · Cited by 343
TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer
Tang, Q., Chen, J., Di, Z., Yuan, W., Zhou, Z., Liu, Z., Han, S., Liu, Y., Ying, G., Shu, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01690-z · Cited by 342
The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental model
Ribatti, D. (2016) · Mechanisms of Development · doi:10.1016/j.mod.2016.05.003 · Cited by 341
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
To, C., Jang, J., Chen, T., Park, E., Mushajiang, M., De Clercq, D. J. H., Xu, M., Wang, S., Cameron, M. D., Heppner, D. E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0903 · Cited by 330
Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1736 · Cited by 327
Exosome-mediated breast cancer chemoresistance via miR-155 transfer
Santos, J. C., Lima, N. D. S., Sarian, L. O., Matheu, A., Ribeiro, M. L., & Derchain, S. F. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19339-5 · Cited by 325
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323
Real, P. J., Sierra, A., de Juan, A., Segovia, J. C., Lopez-Vega, J. M., & Fernandez-Luna, J. L. (2002) · Oncogene · doi:10.1038/sj.onc.1206004 · Cited by 321
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Nishio, M., Endo, T., Tsukada, N., Ohata, J., Kitada, S., Reed, J. C., Zvaifler, N. J., & Kipps, T. J. (2005) · Blood · doi:10.1182/blood-2004-03-0889 · Cited by 317
Targeted Therapies for Triple-Negative Breast Cancer
Lyons, T. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0682-x · Cited by 311
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw042 · Cited by 306
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice
Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.064 · Cited by 292
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
Wang, J., & Wu, G. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558288 · Cited by 291
Wen, Y.-A., Xing, X., Harris, J. W., Zaytseva, Y. Y., Mitov, M. I., Napier, D. L., Weiss, H. L., Mark Evers, B., & Gao, T. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.21 · Cited by 291
Peetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
Fu, D., Wang, C., Yu, L., & Yu, R. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00271-y · Cited by 283
Dong, X., Pan, P., Zheng, D.-W., Bao, P., Zeng, X., & Zhang, X.-Z. (2020) · Science Advances · doi:10.1126/sciadv.aba1590 · Cited by 282
Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 279
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
Rathore, R., McCallum, J. E., Varghese, E., Florea, A.-M., & Büsselberg, D. (2017) · Apoptosis · doi:10.1007/s10495-017-1375-1 · Cited by 277
Monk, B. J., Mas Lopez, L., Zarba, J. J., Oaknin, A., Tarpin, C., Termrungruanglert, W., Alber, J. A., Ding, J., Stutts, M. W., & Pandite, L. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9571 · Cited by 264
Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 264
A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells
Shen, S., Xu, X., Lin, S., Zhang, Y., Liu, H., Zhang, C., & Mo, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00793-0 · Cited by 264
Lipoic acid biosynthesis defects
Mayr, J. A., Feichtinger, R. G., Tort, F., Ribes, A., & Sperl, W. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9705-8 · Cited by 263
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., et al. (2010) · Cancers · doi:10.3390/cancers2031717 · Cited by 260
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Han, W., Pan, H., Chen, Y., Sun, J., Wang, Y., Li, J., Ge, W., Feng, L., Lin, X., Wang, X., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018691 · Cited by 256
Different strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
McCoach, C. E., Le, A. T., Gowan, K., Jones, K., Schubert, L., Doak, A., Estrada-Bernal, A., Davies, K. D., Merrick, D. T., Bunn, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2452 · Cited by 247
Bioinspired and Biomimetic Nanomedicines
Chen, Z., Wang, Z., & Gu, Z. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00079 · Cited by 242
Self-citationWang, J.-Q., Yang, Y., Cai, C.-Y., Teng, Q.-X., Cui, Q., Lin, J., Assaraf, Y. G., & Chen, Z.-S. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100743 · Cited by 241
Self-citationTreg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
Han, H., Hou, Y., Chen, X., Zhang, P., Kang, M., Jin, Q., Ji, J., & Gao, M. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c00650 · Cited by 231
Chen, T.-C., Chuang, J.-Y., Ko, C.-Y., Kao, T.-J., Yang, P.-Y., Yu, C.-H., Liu, M.-S., Hu, S.-L., Tsai, Y.-T., Chan, H., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101413 · Cited by 228
Classification Systems of Secondary Active Transporters
Perland, E., & Fredriksson, R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.008 · Cited by 224
Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch
Ouadah, Y., Rojas, E. R., Riordan, D. P., Capostagno, S., Kuo, C. S., & Krasnow, M. A. (2019) · Cell · doi:10.1016/j.cell.2019.09.010 · Cited by 224
Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan
Misra, S., Ghatak, S., Zoltan-Jones, A., & Toole, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300173200 · Cited by 221
β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6390 · Cited by 220
Jin, H., He, Y., Zhao, P., Hu, Y., Tao, J., Chen, J., & Huang, Y. (2019) · Theranostics · doi:10.7150/thno.27246 · Cited by 218
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)
Gupta, A., Roy, S., Lazar, A. J. F., Wang, W.-L., McAuliffe, J. C., Reynoso, D., McMahon, J., Taguchi, T., Floris, G., Debiec-Rychter, M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000248107 · Cited by 217
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Liu, W.-J., Du, Y., Wen, R., Yang, M., & Xu, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 216
The multifaceted role of glutathione S-transferases in cancer
Chatterjee, A., & Gupta, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.028 · Cited by 215
Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L., & Sherman, R. E. (2014) · JAMA · doi:10.1001/jama.2013.282542 · Cited by 214
Tew, K. D., Bomber, A. M., & Hoffman, S. J. (1988) · PubMed · Cited by 211
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Ascierto, M. L., McMiller, T. L., Berger, A. E., Danilova, L., Anders, R. A., Netto, G. J., Xu, H., Pritchard, T. S., Fan, J., Cheadle, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0072 · Cited by 210
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Song, M., Cui, M., & Liu, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114205 · Cited by 205
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update
Engle, K., & Kumar, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114542 · Cited by 205
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
Chen, Y., Jacamo, R., Konopleva, M., Garzon, R., Croce, C., & Andreeff, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66553 · Cited by 202
Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?
Rochat, B., Morsman, J. M., Murray, G. I., Figg, W. D., & McLeod, H. L. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38762-2 · Cited by 200
Molecular mechanisms of drug resistance in ovarian cancer
Norouzi‐Barough, L., Sarookhani, M. R., Sharifi, M., Moghbelinejad, S., Jangjoo, S., & Salehi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26289 · Cited by 200
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance
Giddings, E. L., Champagne, D. P., Wu, M.-H., Laffin, J. M., Thornton, T. M., Valenca-Pereira, F., Culp-Hill, R., Fortner, K. A., Romero, N., East, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23071-6 · Cited by 199
Zhang, J., Cai, H., Sun, L., Zhan, P., Chen, M., Zhang, F., Ran, Y., & Wan, J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0864-6 · Cited by 197
Wei, F., Zhang, T., Deng, S.-C., Wei, J.-C., Yang, P., Wang, Q., Chen, Z.-P., Li, W.-L., Chen, H.-C., Hu, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.022 · Cited by 197
Self-citationDu, J., Wang, X., Li, Y., Ren, X., Zhou, Y., Hu, W., Zhou, C., Jing, Q., Yang, C., Wang, L., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03996-y · Cited by 197
Kipps, T. J., Eradat, H., Grosicki, S., Catalano, J., Cosolo, W., Dyagil, I. S., Yalamanchili, S., Chai, A., Sahasranaman, S., Punnoose, E., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1030638 · Cited by 196
Wu, Q., Ma, J., Wei, J., Meng, W., Wang, Y., & Shi, M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.011 · Cited by 195
Oncogene-induced senescence: a double edged sword in cancer
Liu, X.-L., Ding, J., & Meng, L.-H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.198 · Cited by 190
Targeting cancer with antibody-drug conjugates: Promises and challenges
Dean, A. Q., Luo, S., Twomey, J. D., & Zhang, B. (2021) · mAbs · doi:10.1080/19420862.2021.1951427 · Cited by 190
Neufeld, L., Yeini, E., Reisman, N., Shtilerman, Y., Ben-Shushan, D., Pozzi, S., Madi, A., Tiram, G., Eldar-Boock, A., Ferber, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi9119 · Cited by 189
Honecker, F., Wermann, H., Mayer, F., Gillis, A. J. M., Stoop, H., van Gurp, R. J. L. M., Oechsle, K., Steyerberg, E., Hartmann, J. T., Dinjens, W. N. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8623 · Cited by 188
Cytochrome P450 CYP1B1 protein expression:
McFadyen, M. C. E., McLeod, H. L., Jackson, F. C., Melvin, W. T., Doehmer, J., & Murray, G. I. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00643-8 · Cited by 188
Chaudhary, N., Choudhary, B. S., Shah, S. G., Khapare, N., Dwivedi, N., Gaikwad, A., Joshi, N., Raichanna, J., Basu, S., Gurjar, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33711 · Cited by 185
Luo, J., Yao, J.-F., Deng, X.-F., Zheng, X.-D., Jia, M., Wang, Y.-Q., Huang, Y., & Zhu, J.-H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0694-6 · Cited by 182
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Huo, X., Jiang, S., Wu, S., Lian, Q., & Chen, H. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.002 · Cited by 12
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Metadata
- Authors
- Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2023-05-22
- Volume
- 4
- Issue
- 3
- Pages
- e265-e265
- ISSN
- 2688-2663 (ISSN-L)
- OpenAlex
- W4378082489
- Cited by
- 347
- References
- 413
- FWCI
- 35.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.